Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.

[1]  M. Cazzola,et al.  Translational Study Searching for Synergy between Glycopyrronium and Indacaterol , 2014, COPD.

[2]  M. Cazzola,et al.  Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond , 2014, Expert opinion on drug discovery.

[3]  M. Cazzola,et al.  Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. , 2014, American journal of respiratory cell and molecular biology.

[4]  E. Bateman,et al.  Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study , 2014 .

[5]  S. Rennard,et al.  The AUGMENT COPD Trial: Efficacy and Safety of a Fixed-Dose Combination of Aclidinium Bromide and Formoterol Fumarate in COPD Patients , 2014 .

[6]  M. Cazzola,et al.  New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol , 2013, Drug design, development and therapy.

[7]  M. Cazzola,et al.  Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  E. Rendina,et al.  The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. , 2013, Pulmonary pharmacology & therapeutics.

[9]  D. Tashkin,et al.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.

[10]  A. Halayko,et al.  Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. , 2013, Pulmonary pharmacology & therapeutics.

[11]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[12]  M. Cazzola,et al.  High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. , 2012, American journal of respiratory cell and molecular biology.

[13]  J. Castro‐Rodriguez,et al.  Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. , 2012, Pulmonary pharmacology & therapeutics.

[14]  M. Cazzola,et al.  Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma , 2012, Journal of Pharmacology and Experimental Therapeutics.

[15]  M. Cazzola,et al.  Pharmacological characterization of adenosine receptors on isolated human bronchi. , 2011, American journal of respiratory cell and molecular biology.

[16]  M. Cazzola,et al.  Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. , 2011, American journal of respiratory cell and molecular biology.

[17]  P. Casarosa,et al.  Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs , 2011 .

[18]  M. Cazzola,et al.  Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi , 2011, British journal of pharmacology.

[19]  M. Cazzola,et al.  Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. , 2011, Pulmonary pharmacology & therapeutics.

[20]  M. Cazzola,et al.  The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.

[21]  Soo-il Lee,et al.  Drug interaction: focusing on response surface models , 2010, Korean journal of anesthesiology.

[22]  P. Casarosa,et al.  Addition Of The New Once-daily LABA BI 1744 To Tiotropium Results In Superior Bronchoprotection In Pre-clinical Models , 2010, ATS 2010.

[23]  M. Cazzola,et al.  Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. , 2009, Pulmonary pharmacology & therapeutics.

[24]  M. Cazzola,et al.  Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function , 2009, COPD.

[25]  M. Bolli,et al.  Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist , 2008, Journal of Pharmacology and Experimental Therapeutics.

[26]  M. Cazzola,et al.  Novel long‐acting bronchodilators for COPD and asthma , 2008, British journal of pharmacology.

[27]  M. Cazzola,et al.  Effects of neuraminidase on equine isolated bronchi. , 2008, Pulmonary pharmacology & therapeutics.

[28]  P. Barnes,et al.  Small airways: an important but neglected target in the treatment of obstructive airway diseases. , 2008, Trends in pharmacological sciences.

[29]  John C. Boik,et al.  Quantifying synergism/antagonism using nonlinear mixed‐effects modeling: A simulation study , 2008, Statistics in medicine.

[30]  Carolina Johansson,et al.  A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  G. Rossoni,et al.  Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. , 2007, Pulmonary pharmacology & therapeutics.

[32]  M. Hori,et al.  Acute heart failure: inotropic agents and their clinical uses , 2006, Expert opinion on pharmacotherapy.

[33]  V. Tam,et al.  Mathematical formulation of additivity for antimicrobial agents. , 2006, Diagnostic microbiology and infectious disease.

[34]  M. Cazzola,et al.  Immune sensitization of equine bronchus: glutathione, IL-1β expression and tissue responsiveness , 2005, Respiratory research.

[35]  A. Christopoulos,et al.  Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting , 2004 .

[36]  P. Barnes.  Distribution of receptor targets in the lung. , 2004, Proceedings of the American Thoracic Society.

[37]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[38]  Paul E. Verweij,et al.  In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[39]  E. van Lunteren,et al.  Auxotonic contractile responses of rat tracheal and bronchial airway smooth muscle. , 2001, Pulmonary pharmacology & therapeutics.

[40]  R. Tallarida,et al.  Drug synergism: its detection and applications. , 2001, The Journal of pharmacology and experimental therapeutics.

[41]  S. Uhlig,et al.  Immediate allergic response in small airways. , 2001, American journal of respiratory and critical care medicine.

[42]  I. Wakabayashi,et al.  Ethanol suppresses L-arginine-induced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide. , 2000, Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.

[43]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[44]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[45]  J. D. de Jongste,et al.  Studies of human airways in vitro: a review of the methodology. , 1993, Journal of pharmacological and toxicological methods.

[46]  Berenbaum Mc.  What is synergy? , 1989, Pharmacological reviews.

[47]  S. Muldoon,et al.  Contractile properties of isolated vascular smooth muscle after photoradiation. , 1989, The American journal of physiology.

[48]  M. Berenbaum.  What is synergy? , 1989, Pharmacological reviews.